Drug Combination May Have Potential for Cancers with TP53 Mutations - Cancer Currents Blog

National Cancer Institute sent this bulletin at 04/04/2024 10:36 AM EDT

Having trouble viewing this email? View it as a Web page.

Drug Combination May Have Potential for Cancers with TP53 Mutations
04/04/2024
	Although TP53 mutations help drive the growth of most cancers, there are no FDA-approved therapies that target altered p53 proteins. Now a drug combination has shown promise in mice and is being tested in a clinical trial.

You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.